Evidence map›Paper›PMID 42232990›Full record

ArticleBlood neoplasia2026

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Rami S Komrokji, Zena Komrokji, Najla H Al Ali, Zhuoer Xie, Onyee Chan, Andrew T Kuykendall, Alison R Walker, Seongseok Yun, Sam B Reynolds, Rory Shallis and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rami S KomrokjiDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Zena KomrokjiDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Najla H Al AliDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Zhuoer XieDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Onyee ChanDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Andrew T KuykendallDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Alison R WalkerDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Seongseok YunDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Sam B ReynoldsDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Rory ShallisDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Jeffrey E LancetDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
David A SallmanDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Eric PadronDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization and international consensus 2022 classifications have proposed lowering the absolute monocyte count threshold to ≥ 0.5 × 109/L for the diagnosis of chronic myelomonocytic leukemia (CMML). This was based on reports describing patients with oligomonocytic CMML (O-CMML) (0.5 × 109/L to 1.0 × 109/L) as a CMML variant. We identified patients among the myelodysplastic syndrome (MDS) database with O-CMML who meet the new criteria for CMML and compared them to MDS and CMML (≥1.0 × 109/L). Among 1861 patients with MDS, 468 (25%) were O-CMML meeting new CMML criteria. The genomic landscape of O-CMML was more comparable to MDS. Classical CMML somatic mutations (

Identifiers

PMID42232990
PMCPMC13223902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.